Vantage logo

Bispecifics move beyond cancer

Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.